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Abstract
Background: We have previously reported that the expression of the messenger ribonucleic acid
(mRNA) for the NR2A subunit of the N-methyl-D-aspartate (NMDA) class of glutamate receptor
was decreased in a subset of inhibitory interneurons in the cerebral cortex in schizophrenia. In this
study, we sought to determine whether a deficit in the expression of NR2A mRNA was present in
the subset of interneurons that contain the calcium buffer parvalbumin (PV) and whether this deficit
was associated with a reduction in glutamatergic inputs in the prefrontal cortex (PFC) in
schizophrenia.
Methods: We examined the expression of NR2A mRNA, labeled with a 35S-tagged riboprobe, in
neurons that expressed PV mRNA, visualized with a digoxigenin-labeled riboprobe via an
immunoperoxidase reaction, in twenty schizophrenia and twenty matched normal control subjects.
We also immunohistochemically labeled the glutamatergic axon terminals with an antibody against
vGluT1.
Results: The density of the PV neurons that expressed NR2A mRNA was significantly decreased
by 48-50% in layers 3 and 4 in the subjects with schizophrenia, but the cellular expression of NR2A
mRNA in the PV neurons that exhibited a detectable level of this transcript was unchanged. In
addition, the density of vGluT1-immunoreactive boutons was significantly decreased by 79% in
layer 3, but was unchanged in layer 5 of the PFC in schizophrenia.
Conclusion: These findings suggest that glutamatergic neurotransmission via NR2A-containing
NMDA receptors on PV neurons in the PFC may be deficient in schizophrenia. This may disinhibit
the postsynaptic excitatory circuits, contributing to neuronal injury, aberrant information flow and
PFC functional deficits in schizophrenia.
Background
The prefrontal cortex (PFC) plays an important role in the
temporal organization of behavior [1,2] by temporarily
maintaining "on-line" internal representations of percep-
tual, cognitive and emotive information in order to guide
sequential, contextually meaningful behavior [3]. This
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"executive functioning" capacity forms the basis of many
daily human activities, such as planning, reasoning and
thinking, and is known to be impaired in patients with
schizophrenia [4].
Sustained discharge of neuronal circuits is thought to be
the physiological substrate that mediates on-line mainte-
nance and manipulation of information performed by the
PFC [1,2]. Inhibitory neurons that utilize γ-aminobutyric
acid (GABA) as neurotransmitter play a key role in regu-
lating sustained neuronal activation by dynamically
adjusting the conductances of the pyramidal neuronal
network. Importantly, the number of N-methyl-D-aspar-
tate (NMDA) glutamate receptors within a neural net-
work, including those that are localized on GABA
neurons, appears to be a critical determinant of the stabil-
ity of the network in sustaining neuronal activation [5-9].
GABA neurons receive feedback excitatory modulation via
local recurrent excitatory projections from the pyramidal
neurons they innervate and, at the same time, they are
also targets of feedforward excitatory modulation from
axonal projections furnished by other pyramidal neurons,
located both within the PFC and in other cortical areas
[10-12]. The integrity of PFC functions therefore depends
on the delicate interplay of feedback and feedforward
mechanisms of modulation of cortical inhibitory activi-
ties via activation of glutamate receptors on GABA
interneurons [8,9,13,14].
There has been compelling evidence suggesting that GABA
neurons in the PFC are functionally disturbed in schizo-
phrenia [15-18]. In addition, disturbances of glutamater-
gic modulation of these neurons could further
compromise their normal functioning. In fact, we have
recently found that, in both the PFC and anterior cingu-
late cortex, the expression of the mRNA for the NR2A sub-
unit of the NMDA glutamate receptor was decreased to a
level that was no longer experimentally detectable in 49-
73% of the GABA neurons that normally expressed this
transcript in subjects with schizophrenia [19,20]. Because
connectionally and functionally distinct subpopulations
of GABA neurons regulate different aspects of information
flow in the cerebral cortex [21-23], an important question
that must be addressed in order to truly appreciate the
pathophysiologic consequences of altered glutamatergic
modulation of GABA neuronal functions in schizophre-
nia is the identity of the GABA cells that are affected.
Increasing evidence suggests that the subset of GABA cells
that contain the calcium buffering protein parvalbumin
(PV), which exhibit fast-spiking firing properties and tar-
get the perisomatic (basket cells) and axo-axonic (chande-
lier cells) compartments of pyramidal neurons [24,25],
are functionally disturbed in schizophrenia [17,26], and
these cells express NR2A [27-29]. In this study, using dou-
ble in situ hybridization, we found that the density of
NR2A mRNA-expressing PV neurons was decreased by as
much as 50% in subjects with schizophrenia in a layer-
specific manner. In addition, we immunohistochemically
labeled glutamatergic terminals with an antibody against
the vesicular glutamate transporter vGluT1 [30,31]. We
found that the density of these terminals also exhibited a
reduction with a laminar pattern that paralleled the reduc-
tion in the NR2A-expressing PV neurons. Together these
observations suggest that glutamatergic innervation of PV-
containing inhibitory neurons appears to be deficient in
schizophrenia.
Methods
Human Subjects
Post-mortem brains from subjects whose next of kin had
given consent for their tissues to be used in medical
research were obtained from the Harvard Brain Tissue
Resource Center at McLean Hospital, Belmont, Massachu-
setts. The informed consent process has been approved by
the McLean Hospital Human Research Committee. Com-
parison group brains were collected from subjects diag-
nosed with schizophrenia (n = 20) and normal control
subjects (n = 20) matched for age, postmortem interval
(PMI), brain pH and wherever possible, sex and hemi-
spheric laterality. All brains were examined by a neu-
ropathologist to rule out any neurologic conditions
(Additional file 1).
Diagnosis of schizophrenia was made by reviewing medi-
cal records and an extensive family questionnaire that
included medical, psychiatric and social history. Two psy-
chiatrists (Drs. T.-U. W. Woo and F. M. Benes) reviewed all
records and applied the criteria of Feighner et al. [32] for
the diagnosis of schizophrenia and DSM III-R criteria for
the diagnosis of schizoaffective disorder. Seventeen of the
20 schizophrenia subjects were on antipsychotic medica-
tions at the time of death. Some of these subjects were
receiving concomitant psychotropic medications, such as
anticonvulsants, mood stabilizers, antidepressants or anx-
iolytics (Additional file 1). None of the normal control
subjects was on any psychotropics at the time of death.
Toxicology data together with clinical information con-
firmed that none of the subjects in each group suffered
from any substance-related disorders at the time of death.
Double In Situ Hybridization
Tissue Preparation
Tissue blocks, each about 3 mm in thickness, were
removed from Brodmann's Area 9 of fresh brain speci-
mens and fixed in 0.1% paraformaldehyde in ice-cold 0.1
phosphate buffer saline (PBS; pH 7.4) for 90 minutes,
immersed in 30% sucrose in the same buffer overnight,
and then frozen in Tissue Tek OCT (Sakura Finetek, Tor-
rance, CA). Sections of 10 μm were cut on a cryostat,BMC Psychiatry 2009, 9:71 http://www.biomedcentral.com/1471-244X/9/71
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mounted on slides, and stored at -70°C until use. Two sec-
tions per subject were used for in situ hybridization.
Riboprobe Preparation
Radiolabeled cRNA probe for NR2A
The complementary RNA (cRNA) probes were transcribed
in vitro from full-length complementary DNA (cDNA)
clones of the rat NR2A (Genbank Accession No. M91561)
subunit (kindly provided by Dr. Christine Konradi),
which is 89% identical to the human sequence, as
described previously [19,20]. This same riboprobe was
used in our previously published studies [19,20,33].
Briefly, the probe was derived from a cDNA spanning
nucleotides 1185 to 2154 within the coding region of the
gene. A corresponding sense probe was also generated and
hybridization of the sense probe resulted in no specific
labeling. Radiolabeled cRNA was prepared by first drying
down [35S]UTP (500 mCi/ml of probe, Perkin Elmer Life
and Analytical Sciences Inc, Boston, Mass) in a DNA
Speed-Vac (Savant, Farmingdale, NY). 100 ng/ml of the
cDNA template, 0.1 M dithiothreitol (DTT), 3 U/ml of
RNasin, 5 mM NTPs, 0.8 U/ml T3 or T7 polymerases (for
antisense and sense probe respectively), and 5× transcrip-
tion buffer were then added. The transcription mixture
was subsequently incubated at 37°C for 2 hours. The
cDNA template was digested by incubating the mixture
with R1Q DNAse at 37°C for 15 minutes. Unincorporated
NTPs were removed by running the mixture through a
Stratagene Nuc-Trap (La Jolla, CA) push column. The elu-
ate was collected, and probe concentration was deter-
mined by scintillation counting. The probe was stored at -
20°C until use.
Digoxigenin (DIG)-labeled cRNA probe for PV
A single PCR product of 510 bp (spanning nucleotides 51-
560) within the coding region of the human parvalbumin
gene (Genbank Accession No. NM_002854.2) was ampli-
fied from human brain cDNA. DIG-UTP-labeled cRNA
probes were transcribed using 100 ng of linearized parval-
bumin cDNA subclones in the presence of 0.1 M DTT, 3
U/ml RNasin, 0.8 U/ml of T3 and T7 RNA polymerases,
10 mM of ATP, CTP, and GTP, 6.5 mM of UTP, and 3.5
mM of DIG-labeled UTP (Roche, Indianapolis, IN). The
mixture was incubated at 37°C for 2 hours. cDNA tem-
plate was digested with RQ1 DNase. The sense probe was
also generated as control.
Hybridization
Sections were hybridized in a buffer consisting of 50%
formamide, 0.1% yeast transfer (t)RNA, 10% dextran sul-
fate, 1× Denhardt's solution, 0.5 M/l ethylenediamine tet-
racetic acid (EDTA), 0.02% sodium dodecyl sulfate (SDS),
4× saline-sodium citrate buffer (SSC), 10 mM dithiothre-
itol (DTT), and 0.1% single stranded DNA (ssDNA) at a
final concentration of 0.4 ng probe/ml hybridization
buffer. They were then post-fixed in 4% paraformalde-
hyde for 10 minutes and incubated in 0.1 M trieth-
anolamine (TEA) for 5 minutes at room temperature
before being dehydrated in a graded series of ethanol.
Probes were then added to slides for hybridization in a
prewarmed, humidified dish. Sections were covered with
coverslips and incubated at 56°C for 12 hours in a humid
chamber. At the end of hybridization, coverslips were
soaked off in 4× SSC in the presence of 100 μl of β-mer-
captoethanol (βMer). Tissue was then incubated in 0.5 M
NaCl/0.05 M phosphate buffer for 10 minutes, 0.5 M
NaCl with 0.025 mg/ml RNaseA at 37°C for 30 minutes,
followed by a high stringency wash with a solution con-
taining 50% formamide, 0.5 M NaCl/0.05 M phosphate
buffer, and 100 ml βMer at 63°C for 30 minutes. Sections
were finally washed overnight in 0.5× SSC with 20 mM
βMer at room temperature.
Visualization of DIG labeling
After incubation in blocking buffer (100 mM Tris-HCl,
150 mM NaCl [pH 7.5]), the sections were placed in
buffer containing 3% normal donkey serum + 0.3% Tri-
ton X100), and incubated overnight at 4°C in buffer con-
taining 1:200 dilution of sheep anti-DIG antibody
conjugated with peroxidase enzyme (Roche Diagnostics,
Indianapolis, IN). Sections were washed in buffer and a
peroxidase reaction product was localized 3,3'-diami-
nobenzidine tetrahydrochloride in the presence of H2O2.
Emulsion Autoradiography
Slides were apposed to X-ray film (Kodak Biomax MS) for
10 days to determine the presence of sufficient autoradio-
graphic signal. The microscope slides were then dipped in
emulsion, dried and exposed at 4°C in the dark for 5
weeks. They were then developed in Kodak D-19 devel-
oper, counterstained and coverslipped.
Quantification of Cell Density
The slides were coded so that the diagnosis of each case
was unknown to the investigator (BKYB). [35S]-labeling of
NR2A mRNA appeared as clusters of silver grains after
emulsion autoradiography processing. Quantification
was performed as previously described [19,20,33,34].
DIG labeling, in the form of a brown reaction product,
was visualized under a bright field microscope equipped
with polarizing filters to enhance the optical density of the
reaction product. Neurons that were single labeled with
DIG and those that were double labeled with DIG and
[35S] were identified on images captured on a computer
screen using a microscope (Laborlux, Leica Microsystems,
Wetzlar, Germany) fitted with a solid CCD video camera
and connected to a Bioquant Nova Image Analysis System
(R&M Biometrics, Memphis, TN). A touch counting sub-
routine was used to determine the distribution of both
single and double-labeled neurons within a 250 μm-wideBMC Psychiatry 2009, 9:71 http://www.biomedcentral.com/1471-244X/9/71
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cortical traverse extending from the pial surface to the
white matter border by using a X100 oil immersion objec-
tive lens at a final magnification of 1,000×. Two cortical
traverses per section and therefore four cortical traverses
per case were analyzed. For each case, cell counts averaged
from the four cortical traverses were used in statistical
analysis, so that each individual had only one representa-
tive measurement at each cortical depth. Neighboring sec-
tions were stained with cresyl violet for determination of
laminar boundaries. Densities of both single and double-
labeled neurons for each cortical layer were then obtained
by dividing cell counts by laminar areas. Prior to the
actual data collection, intrarater reliability, as assessed by
counting and recounting profiles in the same column, was
established to be above 95%.
To quantify the expression level of mRNA for the NR2A
subunit in individual PV cells, the area occupied by each
grain cluster was carefully outlined using a cursor dis-
played on the computer monitor, as previously described
[19,20,33,34]. The cluster area was measured by high-
lighting the grains with a thresholding subroutine. All
parameters were held constant throughout the entire
course of quantification. The area covered by autoradio-
graphic grains within the cluster area was automatically
computed by the Bioquant software based on the thresh-
old value and was represented as a pixel count for NR2A
transcript expression level. The pixel count was expressed
as a function of cluster area after correcting for back-
ground (i.e. pixel count of the area covered by autoradio-
graphic grains per unit area in square micrometers in the
white matter). The average NR2A expression level in PV
neurons was computed for each cortical layer.
vGluT1 Immunohistochemistry
Tissue blocks containing Brodmann's Area 9 were fixed in
ice cold 4% paraformaldehyde overnight, cryoprotected
in 30% sucrose, embedded in Tissue Tek OCT (Sakura
Finetek, Torrance, CA), and sectioned at 40 μm on a
microtome. The entire experiment was completed in 2
runs. During each run, two sections per subject were used
and all sections from each subject pair were processed
together. Free-floating sections were rinsed for 15 min in
0.3% H2O2, 0.5% Triton-X, and 10% methanol in PBS.
They were then pre-incubated for 30 minutes in 5% nor-
mal horse serum and 0.3% Triton-X in PBS. Sections were
subsequently incubated at room temperature overnight in
a polyclonal rabbit anti-vGluT1 antibody (1:1000)
diluted in 2% normal horse serum and 0.5% Triton-X in
PBS. The specificity of the antibody has been extensively
characterized [30,31,35,36]. After incubation, sections
were rinsed in PBS and incubated at room temperature for
2 hours in biotinylated donkey anti-rabbit IgG (1:500;
Jackson ImmunoResearch Laboratories, West Grove, PA)
in 2% normal horse serum and 0.5% Triton X-100 in PBS.
They were then rinsed in PBS and incubated for 2 hours in
ABC Elite (1:500; Vector Laboratories, Burlingame, CA) in
PBS. vGluT1 elements were visualized with 0.4 mg/mL
DAB (Sigma, St. Louis, MO), 0.0006% hydrogen perox-
ide, and 0.4 mg/mL nickel ammonium sulfate dissolved
in PBS. Sections were mounted, air-dried, dehydrated,
cleared in xylenes and coverslipped.
Quantification
All microscopic analyses were conducted under strictly
blind condition. Sampling was performed in layers 3 and
5 within two 500 μm-wide traverses, 500 μm apart from
one another. Laminar boundaries were determined by
comparing with neighboring Nissl-stained sections.
Quantification was performed using a Leica Laborlux
microscope equipped with a solid-state video camera and
Bioquant Nova Image Analysis System. Using a X100 oil
immersion objective lens, the areas covered by vGluT1-
immunoreactive boutons were outlined, computed and
represented as pixel counts. Density measure per section
was computed by averaging the measurements obtained
from the two 500 μm-wide traverses. The density for each
subject was obtained by averaging the measurements
from all 4 sections.
Statistical Analysis
The densities of PV mRNA+ and PV mRNA+/NR2A
mRNA+ neurons and the NR2A mRNA expression level in
PV+ neurons were compared between both groups across
layers 2 through 6 using repeated-measures analysis of
variance (ANOVA) with diagnosis and layer as main
effects. Layer 1 was not included as no PV+ neurons were
found in this layer. The density of vGluT1-immunoreac-
tive boutons was compared between the two diagnosis
groups, using unpaired t-tests. Analyses were performed
using the JMP 5.1 (SAS Institute, Cary, NC) software pro-
gram and all statistical tests were conducted with α = 0.05.
Confounding Variables
For both in situ hybridization and immunohistochemical
experiments, we evaluated the effects of confounding var-
iables, such as age, PMI, brain, pH, freezer storage time
and exposure to antipsychotic medication (expressed as
chloropromazine equivalent dose or CED) using analysis
of covariance (ANCOVA). Because none of the conclu-
sions derived from our findings were affected by the
ANCOVA analysis, only results from repeated-measures
ANOVAs are reported. In addition, Pearson's correlation
was used to assess if there was any linear relationship
between cell, grain or vGluT1-immunoreactive bouton
densities and any of the continuous variables. Effects of
hemispheric laterality and sex were evaluated by using 2-
tailed unpaired t tests to compare the measures from the
two hemispheres within individual groups.BMC Psychiatry 2009, 9:71 http://www.biomedcentral.com/1471-244X/9/71
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Results
Distribution of PV mRNA+ and PV mRNA+/NR2A mRNA+ 
Neurons
Neurons that expressed PV mRNA were present predomi-
nantly in layers 3, 4 and 5 and were also observed in layers
2 and 6, but were absent from layer 1. The PV mRNA+/
NR2A mRNA+ neurons seemed to be most concentrated
in layers 3 and 4 (Figure 1).
Density of PV mRNA+/NR2A mRNA+ Neurons
The effect of diagnosis was significant (F = 6.62; df = 1, 38;
P = 0.01). Furthermore, this effect was layer specific (F =
3.75; df = 1, 38; P = 0.006). Thus, in the subjects with
schizophrenia, the density of the double-labeled neurons
was significantly decreased by 48% and 50% in layers 3 (t
= -2.11, P = 0.04) and 4 (t = -2.15, P = 0.03), respectively
(Figure 2).
Density of PV mRNA+ Neurons
Consistent with previous observations [26,37], we found
that the number of cells that expressed a detectable level
of PV mRNA was not altered in subjects with schizophre-
nia (F = 3.35; df = 1, 38; P = 0.07). The use of digoxigenin
to label PV mRNA, however, precluded us from address-
ing any possible alteration in transcript expression level
per neuron, as has been reported previously [26].
Cellular Expression of NR2A mRNA
The density of silver grains per neuron did not differ
between the schizophrenia and normal control groups
(Figure 3). Furthermore, the distributions of the frequency
histograms of NR2A mRNA expression level per PV cell
did not differ between the two study groups (data not
shown). Taken together, it can be concluded that in the PV
cells that expressed a detectable level of NR2A mRNA, the
amount of transcript expression was unaltered in schizo-
phrenia.
vGluT1 Immunoreactive Boutons
The density of vGluT1-immunoreactive boutons in layer 3
of the PFC was significantly decreased by 79% in subjects
with schizophrenia (Figure 4; t = 2.07, P = 0.05).
Confounding Variables
Potential confounding variables (i.e. age, PMI, brain pH,
freezer storage time, hemispheric laterality, antipsychotic
drug exposure, sex and laterality) were evaluated with
respect to the densities of PV mRNA+ and PV mRNA+/
NR2A mRNA+ neurons, and vGluT1-immunoreactive
boutons. None of these factors appear to have influenced
our results.
Discussion
We have extended our previous finding of reduced NR2A
mRNA expression in GABA neurons in schizophrenia
[19,20] to demonstrate that, in the PFC, this reduction
occurs in a subset of PV-containing neurons. Furthermore,
the density of axonal boutons that were immunoreactive
for vGluT1, which is localized to presynaptic terminals
furnished by cortically-originated glutamatergic projec-
tions [30,31,38], also appears to be decreased. Together
these observations suggest that innervation of PV neurons
by corticocortical glutamatergic projections via NMDA
receptors may be deficient in schizophrenia.
The observation of decreased density of the NR2A-
expressing PV neurons might represent a loss of these neu-
rons, but previous studies suggest that cell loss does not
seem to be a prominent feature in the PFC in schizophre-
nia, at least not in large scale [39,40]. Furthermore, con-
sistent with previous observations [26,37], in this study,
we found that the density of PV neurons was unaltered in
schizophrenia subjects. Taken together, our finding is
most consistent with the interpretation that, in a subset of
PV neurons, the expression of NR2A is reduced to a level
that is no longer experimentally detectable.
It has long been known that treatment with NMDA recep-
tor antagonists produces a syndrome that is highly remi-
niscent of the clinical picture of schizophrenia [41,42],
and these data led to the NMDA receptor hypofunction
model [43]. The paradoxical excitotoxic effects originally
observed by Olney and Farber with NMDA antagonists
were explained, at least in part, by blockade of the NMDA
receptors that are located on GABA neurons, which have
been shown to be some 10-fold more sensitive to NMDA
receptor antagonists than the NMDA receptor on pyrami-
dal neurons [43-45]. To this end, a recent study by Kinney
and colleagues found that the amount of NR2A mRNA
expressed in cultured PV neurons was 5-fold higher than
in pyramidal cells [27]. Similarly, compared to other
NMDA subunits, the expression of NR2A appears to be
prevalent in PV neurons [29]. Moreover, NR2A, but not
NR2B selective antagonists, down-regulate GAD67 and PV
mRNA expression in cultured PV neurons [27]. Finally,
NMDA antagonism has been found to decrease the cellu-
lar expression of PV [46-48] and the number of axo-
axonic cartridges [49]. Taken together, our finding of
reduced NR2A expression in PV neurons may, at least in
part, contribute to the reduction in the expression of
GAD67 and PV and the decrease in the density of axon car-
tridges in schizophrenia [26,50-52].
The expression of the mRNA for vGluT1 has been found
to be decreased in the PFC in schizophrenia [53], but neg-
ative results have also been reported [54]. At the protein
level, using Western blot analysis, vGluT1 has been shown
to be unaltered in the PFC, but decreased in the anterior
cingulate cortex in schizophrenia [54]. In this study, we
found that the density of the axonal boutons that wereBMC Psychiatry 2009, 9:71 http://www.biomedcentral.com/1471-244X/9/71
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Plots of PV+/NR2A+ neurons from representative sections from a normal control (A) and a schizophrenia subject (B). Num- bers depict cortical layers Figure 1
Plots of PV+/NR2A+ neurons from representative sections from a normal control (A) and a schizophrenia sub-
ject (B). Numbers depict cortical layers. X = PV mRNA-expressing neurons. O = PV neurons that co-express NR2A 
mRNA
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immunoreacvtive for vGluT1 was decreased in layer 3 of
the PFC in subjects with schizophrenia. A likely explana-
tion for the seeming discrepancy between this study and
the previous report [54] may be attributable to methodo-
logical differences, i.e. immunohistochemistry in combi-
nation with quantification of axonal boutons afforded us
a higher sensitivity in detecting differences in the present
study. In the context of our finding, it is interesting to note
that, a single polymorphism in the neuregulin-1 gene, a
schizophrenia risk gene [55], has recently been reported
to be associated with vGluT1 expression in human post-
mortem brains, with the at-risk allele predicting decreased
expression of the glutamatergic marker [56].
Our observation of reduced vGluT1-immunoreactive bou-
tons in layer 3 indicates that the number of glutamatergic
axon terminals may be decreased in schizophrenia. An
alternative interpretation of this finding is that the bou-
tons may remain structurally intact (i.e. their number
does not change), but they are functionally altered (i.e.
vGluT1 expression is reduced). Because dendritic spines
are the most common target of glutamatergic terminals
[57], and because density of spines on layer 3 pyramidal
cells has been found to be decreased by ~20% in schizo-
phrenia [58], it would appear that our finding of reduced
vGluT1 immunoreactivity reflects, at least in part, a loss of
axon terminals. However, the magnitude of spine loss of
20% is insufficient to account for the current observation
of a 79% reduction in vGluT1 immunoreactivity. Because
up to 85% of all asymmetric synapses (i.e. synapses
formed by glutamatergic terminals) in the cortex are
formed almost exclusively on dendritic spines [59], and
this amount is similar to the magnitude of reduction in
vGluT1-immunoreactive profiles observed in this study,
one interpretation of our finding is that the majority of
the glutamatergic terminals that target pyramidal neurons
in layer 3 of the PFC are functionally disturbed in schizo-
phrenia and, among these terminals, approximately 20%
are lost. Alternatively, but not mutually exclusively, gluta-
(A) Photomicrograph showing examples of PV+/NR2A+ neu- rons Figure 2
(A) Photomicrograph showing examples of PV+/
NR2A+ neurons. Scale bar = 20 μm. (B) Mean (± SEM) 
density of PV+/NR2A+ neurons is significantly decreased in 
layers 3 and 4 in the PFC in schizophrenia.
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Mean (± SEM) density of silver grains over PV+ neurons in  the PFC is not different between the two subject groups,  suggesting that the expression level of NR2A mRNA in PV  cells is unchanged in schizophrenia Figure 3
Mean (± SEM) density of silver grains over PV+ neu-
rons in the PFC is not different between the two sub-
ject groups, suggesting that the expression level of 
NR2A mRNA in PV cells is unchanged in schizophre-
nia.
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(A) Photomicrographs showing vGluT1-immunoreactive  boutons in layer 3 of the PFC Figure 4
(A) Photomicrographs showing vGluT1-immunore-
active boutons in layer 3 of the PFC. Scale bar = 100 
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matergic terminals that target neural structures other than
spines may also be affected. Interestingly, aside from den-
dritic spines, the PV-containing neurons constitute the
prime target of these terminals [11]. Given our finding of
reduced NR2A expression in these neurons, it seems likely
that glutamatergic terminals that are presynaptic to PV
neurons may also be disturbed. In order to definitively
address this hypothesis, however, double immunolabe-
ling in combination with confocal or electron microscopy
will be required.
Deficient glutamatergic inputs to PV neurons could, via
disinhibition [60], lead to increased activity of excitatory
circuits that are postsynaptic to these neurons, rendering
them more vulnerable to excitotoxic or oxidative injury
[8,43,61,62]. Short of leading to cell death, available evi-
dence suggests that cellular injury can be manifested in
the form of neuritic and synaptic atrophy [63-68] and
hence may contribute to the observed reduction in den-
dritic spines [58,69], pyramidal cell somal area [70], syn-
aptic markers [71-76] and volume of neuropil [39] in
schizophrenia. In addition, PV neurons are known to play
a critical role in the orchestration of oscillation of pyram-
idal cell circuits in the gamma frequency band (30-100
Hz), which is thought to be a mechanism that supports
information integration [77-80]. Recent studies increas-
ingly converge upon the notion that gamma oscillation
disturbances represent a prominent pathophysiologic fea-
ture of schizophrenia [81-83]. In addition, animal studies
have shown that NMDA receptor blockade robustly dis-
rupts gamma rhythms in the entorhinal cortex [84] and it
is speculated that this disruption may be mediated by the
NMDA receptors on the PV-containing neurons [84].
Taken together, reduced glutamatergic inputs onto PV
neurons via NMDA receptors may in part contribute to
aberrant gamma oscillations in schizophrenia. However,
it is important to note that the contribution of NMDA
receptor to excitatory neurotransmission onto PV neurons
varies across brain regions [85,86]. This may explain why
the effects of NMDA antagonism on gamma oscillations
are highly region-dependent [87].
Conclusion
Convergent lines of evidence suggest that glutamatergic
neurotransmission on PV-containing neurons via NMDA
receptors appears to be deficient in schizophrenia. Altered
NMDA receptor expression is not restricted to PV neurons.
For example, the expression of NR2A mRNA has also been
found to be altered in the inhibitory neurons that contain
another calcium buffer calbindin [33], which target the
dendrites of pyramidal neurons. Likewise, altered gluta-
mate receptor expression in inhibitory neurons is not con-
fined to the NMDA class; the expression of the mRNA for
the GluR5 kainate receptor in GABA neurons, for instance,
has also been found to be altered [88]. It seems clear that
more studies are needed before we can better define how
cortical circuits are disturbed in schizophrenia, and the
potential functional consequences of these disturbances.
Such knowledge will provide a neurobiologic framework
within which it may be possible to conceptualize rational
therapeutic strategies that aim at normalizing or recali-
brating the malfunctioned brain circuits [89,90].
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